Angiotensin-(1-7) ] is an endogenous, heptapeptide hormone acting through the Mas receptor (MasR), with anti-proliferative and anti-angiogenic properties. Recent studies have shown that Ang-(1-7) has an anti-proliferative action on lung adenocarcinoma cells and prostate cancer cells. In this study, we report that MasR levels were significantly upregulated in nasopharyngeal carcinoma (NPC) specimens and NPC cell lines. Viral vector-mediated expression of Ang- (1-7) dramatically suppressed NPC cell proliferation and migration in vitro. These effects were completely blocked by the specific Ang-(1-7) receptor antagonist A-779, suggesting that they are mediated by the Ang-(1-7) receptor Mas. In the current study, Ang-(1-7) not only caused a significant reduction in the growth of human nasopharyngeal xenografts, but also markedly decreased vessel density, suggesting that the heptapeptide inhibits angiogenesis to reduce tumor size. Mechanistic investigations revealed that Ang-(1-7) inhibited the expression of the pro-angiogenic factors VEGF and PlGF. Taken together, the data suggest that upregulation of MasR could be used as a diagnostic marker of nasopharyngeal carcinoma and Ang-(1-7) may be a novel therapeutic agent for nasopharyngeal cancer therapy since it exerts significant anti-angiogenic activity.
Introduction
Nasopharyngeal carcinoma (NPC) is a common head and neck cancer, which is highly malignant with local invasion and early distant metastasis. NPC is a multifactorial disease. Both genetic predisposition (1) and epigenetic alterations (2) are important for the initiation and progression of NPC. In addition, the pathogenesis of NPC is closely linked to Epstein-Barr virus infection. Tobacco and alcohol consumption are critical risk factors as well (3) . In southern China, the incidence of 4 NPC has remained very high, with a 5-year overall survival rate of approximately 70% (4) . Although its prognosis has improved due to advances in diagnostic and surgical techniques, 30% to 40% of patients will develop distant metastases within 4 years (5).
Once metastasis occurs, the prognosis is very poor and so novel treatment strategies for nasopharyngeal cancer are urgently needed.
Angiotensin-(1-7) [Ang-(1-7)], either produced in the circulation or in tissues, is a biologically active peptide hormone of the renin-angiotensin system with vasodilator, antiproliferative, and antithrombotic properties (6, 7) that are mediated by MasR, a unique G-protein-coupled receptor (8, 9) . It has been shown that Ang-(1-7) reduced the growth of human lung tumor xenografts, with a concomitant decrease in vascular endothelial growth factor (VEGF) and reduced vessel density, as well as decreasing the growth of orthotopic human estrogen receptor positive or HER2 over-expressing breast tumor xenografts (10) (11) (12) (13) . A Phase I clinical trial demonstrated that Ang- (1-7) is a first-in-class antiangiogenic drug with activity for treating cancer that is linked to reduction of plasma placental growth factor (PlGF) levels (14) . Recent studies showed that Ang-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis (15) , and also reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sflt-1 (16) . These findings suggest that Ang-(1-7) reduces tumor size by attenuating proliferation and angiogenesis. Until now, no functional evidence of Ang-(1-7) in NPC has been documented.
Transgenic expression of Ang-(1-7) can be mediated by viral vectors through the use of synthetic fusion protein expression cassettes which are expressed intracellularly and result in cleavage and secretion of active peptides (17) (18) (19) . In this study, we investigated the potential involvement of Ang-(1-7) in NPC using lentiviral or AAV vectors expressing fusion proteins which secrete the heptapeptide. First, we tested its effects on cell growth and migration. Second, we investigated the potential role of Ang-(1-7) on NPC tumorigenesis in a murine model. Finally, we explored the underlying mechanism of Ang-(1-7) actions in NPC. We believe our study will provide a better understanding of NPC pathogenesis. 
Materials and Methods
on
Viral vector construction and preparation
The lentiviral vector Lenti-Ang-(1-7) construct used to produce the Ang-(1-7) was designed, prepared, and titrated as previously described (17, 20, 21) . Both IgG2b and Ang-(1-7) from the fusion protein can be detected intracellularly. The enhanced green fluorescent protein (eGFP) lentiviral vector Lenti-eGFP was used as a control.
Two adeno-associated viral vectors (AAVs), AAV2-chicken β-actin promoter (CBA)-Ang-(1-7) and AAV2-CBA-eGFP, were constructed as detailed previously (22) . The vector plasmid was packaged in AAV serotype 8 containing a Y733F mutation by transfection of HEK 293T cells according to previously published methods (23, 24) . Vector doses were expressed as genome copies.
Clinical specimens
Primary NPC biopsy specimens and normal biopsies of the nasopharynx were obtained from Guangdong NO.2 Provincial People's Hospital (Guangzhou, Guangdong, China). Both tumor and normal tissues were histologically confirmed by H&E (hematoxylin and eosin) staining. Informed consent was obtained from each patient, and the research protocols were approved by the Ethics Committee of Guangdong NO.2 Provincial People's Hospital.
Quantification of secreted Ang-(1-7) by ELISA
The NPC cells were plated at 50% confluence in 24-well culture plates; they were then transduced with Lenti-Ang-(1-7) at a concentration of 200 multiplicities of infection (MOI) in the presence of 8 μg/ml polybrene (Sigma-Aldrich, St Louis, MO, USA). After 6 h of viral transduction, the media was replaced with fresh growth medium. After 3 days, the secreted levels of Ang-(1-7) were measured using a commercially available ELISA kit (Bachem, San Carlos, CA, USA). The same ELISA kits were also used to determine the secreted levels of Ang-(1-7) in sera from mice in vivo.
Quantification of cell proliferation
For the cell counting assay, cells were infected with Lenti-Ang-(1-7) to stably overexpress Ang-(1-7). After 72 hours of transduction, the cells were plated in 24 well plates at 1.0 ×10 4 per well. Cells were harvested on days 1, 2, 3, and 4 from triplicate wells and counted using a hemocytometer, to quantify cell proliferation. 
Colony formation assay

In vitro migration assay
Confluent monolayers of Lenti-Ang-(1-7) transduced CNE-1 and CNE-2 cells were scraped down the center of a 35 mm tissue culture dish with a sterile micropipette tip to create a denuded zone of constant width. Cellular debris was removed with PBS and the adherent cells were incubated in regular media for 48 h. Next, a migration assay was performed as described previously (27) .
Transwell migration assay
A total of 1×10 5 normal or transduced NPC cells were resuspended in serum free RPMI with or without 1.0 μmol/L A-779 and placed in the top portion of a Transwell chamber with 8-μm pores. The lower portion of the chamber contained 10% FBS as a chemoattractant. Next, a transwell migration assay was performed as detailed previously (28) .
RNA isolation, reverse transcription, and quantitative real-time RT-PCR
Total RNA was extracted using an RNeasy Mini-Kit (Qiagen) according to the manufacturer's instructions. Quantitative real-time RT-PCR was performed on an ABI 7500 real-time PCR system (Applied Biosystems) as described previously (29) .
The primers are listed in Supplemental Table S1 . The samples were quantified by the comparative △△C T method by using human GAPDH as the internal standard.
Western blot analysis
Western immunoblots were run as described previously (30 Cell Signaling Technology. Anti-β-actin and the secondary antibodies horseradish peroxidase-conjugated anti-rabbit IgG and anti-mouse IgG were from Sigma-Aldrich. 
Tumor growth assay
Statistical analysis
SPSS 19.0 software was used for statistical analysis. Data are presented as mean ± standard deviation (SD) from 3 to 6 independent experiments. Statistical differences were evaluated by one-way ANOVA followed by Dunnett's post hoc test. The criterion for statistical significance was set at P < 0.05.
Results
MasR was upregulated in human NPC cell lines and clinical specimens
The G-protein coupled, seven transmembrane protein encoded by the MasR gene has been identified as an Ang-(1-7) receptor (8, 9) 
Ang-(1-7) inhibited NPC cell growth and migration
To explore the effect of Ang-(1-7) on cell growth, CNE-1 and CNE-2 cells were transduced with Lenti-Ang-(1-7) or Lenti-eGFP. The expression of Ang-(1-7) was increased in CNE-1 and CNE-2 cells respectively in a dose-dependent manner and (Fig. 2C, 2D ). As demonstrated in the colony formation assay, LentiAng-(1-7) transduced CNE-1 and CNE-2 cells showed many fewer colonies compared with Lenti-eGFP infected cells ( VEGF is one of the major pro-angiogenic factors secreted by cancer cells and it acts to stimulate the growth of new blood vessels from pre-existing vessels. VEGF mRNA was measured by real-time RT-PCR in transduced NPC cells, to determine whether the over-expression of Ang-(1-7) reduces expression of this angiogenic factor. VEGF mRNA was reduced by 57% and 53%, respectively, in Lenti-Ang-(1-7) treated CNE-1 and CNE-2 cells compared to control cells (Fig. 4A, 4B) . Similarly, CNE-1 and CNE-2 cells transduced with Lenti-Ang-(1-7) had respective ~70% and 80% reductions in PlGF mRNA compared to control cells (Fig. 4A, 4B) . Under hypoxic conditions, angiogenesis is primarily regulated by hypoxia inducible factor (HIF-1α)-dependent transcription of VEGF (32) . HIF-1α is one of the primary transcription factors that control this mechanism. In addition, PlGF activates downstream target genes in endothelial cells via HIF-1α in a hypoxia independent manner (33). Here, HIF-1α mRNA was also shown to be significantly decreased in Lenti-Ang- (1-7) transduced NPC cells compared to control cells (Fig. 4A, 4B ). NPC cells compared to controls (Fig. 4C, 4D) , suggesting that this heptapeptide may also attenuate VEGF and PlGF signaling by reducing the number of receptors available to these ligands. VEGF receptor 1 or Flt-1 can be processed to soluble Flt-1 or sFlt-1 by alternative splicing (35) . In contrast to the Ang (1-7)-mediated reduction in membrane associated VEGF receptors, sFlt-1 was significantly increased in LentiAng-(1-7) treated CNE-1 and CNE-2 cells compared to control cells (Fig. 4E) . sFlt-1 is secreted into the circulation and binds to VEGF and PlGF, thereby limiting interaction of these ligands with membrane-bound VEGF receptors. These results suggest that Ang-(1-7) may also attenuate angiogenesis by increasing sFlt-1 to reduce circulating VEGF and PlGF. 
phospho-specific antibodies to determine whether Ang-(1-7) inhibited NPC cell growth by attenuating MAP kinases. Western blot results showed that the p44/42 phosphorylation level in Lenti-Ang-(1-7) treated cells was decreased. The phosphorylation of p38, another MAPK pathway, showed a similar response pattern.
However, the level of JNK phosphorylation was not changed in NPC cells treated with Lenti-Ang-(1-7) (Fig. 4F) . These results suggest that Ang-(1-7) reduces tumor growth, in part, by attenuating p44/42 and p38 MAP kinase activities. in mouse sera was quantified by ELISA. The results indicate that the amount of Ang-
Ang
(1-7) secreted into the sera in the mice treated with AAV-Ang-(1-7) was significantly increased when compared to AAV-eGFP or PBS treated mice, as shown in Figure 5A .
At this dose, Ang-(1-7) was shown to effectively inhibit tumor growth with no side effects. Tumors in the control group of mice continued to grow faster over the 30 day period (Fig. 5B, 5C ), whereas administration of the AAV8 (Y733F)-CBA-Ang-(1-7)
resulted in a significant reduction in tumor volume. By the end of the 30 day treatment period, tumors from mice in the control group were about 2.5-fold larger than tumors from AAV8 (Y733F)-CBA-Ang-(1-7)-treated mice. There were no differences in body weight or pathological abnormalities between the groups (data not shown). The mice were euthanized at the end of the study and the tumors were dissected and weighed. As shown in Figure 5D , the tumors from mice treated with AAV8 (Y733F)-CBA-Ang-(1-7) weighed 60% less than the tumors from mice infused with AAV8 (Y733F)-CBA-eGFP or PBS, demonstrating that Ang-(1-7)
reduces tumor growth. 
Ang-(1-7) reduces cell proliferation in CNE-
Discussion
The objective of this study was to investigate the effects of Ang- (1-7) The second set of experiments clarified that Ang-(1-7) caused a marked decrease in cell proliferation and cell migration (Fig. 2, Supplemental Fig. S1 ) of cultured nasopharyngeal cancer cells. These results are in agreement with findings observed in lung, breast or prostate cancers, in which Ang-(1-7) suppressed cell proliferation and tumor xenografts (11, 13, 15, 16) . However, Ang-(1-7) had no effect on cell growth in human colon adenocarcinoma (36) . These inconsistent results suggested that the role of Ang-(1-7) was possibly tumor specific and highly dependent on its targets in different cancer cells. In our experiments, the growth and migration inhibitory effect of Ang-(1-7) in cultured human NPC cells was completely blocked by A-779 (Fig. 3) .
Ang-(1-7) also reduced the phosphorylation and activation of p44/42 MAPK and p38 MAPK (Fig. 4) 
initiate angiogenesis. Here, we observed decreased HIF-1α mRNA in the tumors from mice treated with AAV8 (Y733F)-CBA-Ang-(1-7) and NPC cells treated with LentiAng- (1-7) . Perhaps, as a consequence of the antiproliferative effects of Ang-(1-7), metabolic activity and oxygen consumption may be reduced leading to decreased HIF-1α, VEGF, and finally angiogenesis. HIF-1α expression can also be regulated by other factors such as mitogen-activated protein kinases which are essential for the direct phosphorylation and activation of HIF-1α and VEGF expression (45).
Hypoxia and the associated induction of HIF-1α also regulate the production of other pro-angiogenic genes including PlGF (32) and play a vital role in tumor vascularization (46). A significant decrease of PlGF mRNA was observed in xenografts from mice treated with AAV8 (Y733F)-CBA-Ang-(1-7) when compared with tumors from control animals (Fig. 6) . We also observed a parallel and significant reduction in NPC cell lines treated with Lenti-Ang- (1) (2) (3) (4) (5) (6) (7) . These data demonstrated that the heptapeptide hormone reduced PlGF production as part of this antiangiogenetic effect. These observations are supported by the findings in a Phase I clinical trial for prostate cancer in which responsive patients administered Ang- (1-7) had reduced circulating PlGF (14) . 
